Education
About Us
Working with TipRanks
Follow Us
Sensus Healthcare, Inc. (SRTS)
:SRTS
Top Page
Sensus Healthcare
(NASDAQ:SRTS)
Rating:63Neutral
Price Target:―
Positive Factors
Growth Initiatives
Sensus Healthcare received heightened interest at key industry trade shows, acting as a catalyst for growth.
Product Efficacy
Positive results from a study highlight the efficacy of combining surgical excision of keloids with adjuvant Superficial Radiation Therapy (SRT) using Sensus' SRT-100, showing no keloid recurrence.
Revenue Performance
Sensus Healthcare reported 1Q25 results with revenue above both consensus and estimates, driven by continued momentum in device shipments and the expansion of its 'Fair Deal' program.
Negative Factors
Competition
SkinCure announced it would be exhibiting a fourth-generation SRT device that would compete with Sensus SRT-100 Vision image-guided SRT offering.
Revenue Decline
Total revenue was $8.3M, representing a 22% YoY decline and missing the projection of $8.7M, with a net loss of $2.6M.
Revenue Estimates
Despite positive momentum, the company is lowering its revenue estimates and 12-month price target due to a slower expected revenue ramp with the inclusion of the Fair Deal Agreement model.
Sensus Healthcare (SRTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$77.79M
Dividend YieldN/A
Average Volume (3M)110.89K
Price to Earnings (P/E)43.7
Beta (1Y)1.12
Revenue Growth24.75%
EPS Growth-61.29%
CountryUS
Employees54
SectorHealthcare
Sector Strength43
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.16
Shares Outstanding16,445,036
10 Day Avg. Volume119,571
30 Day Avg. Volume110,887
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)1.37
Price to Sales (P/S)0.00
P/FCF Ratio15.87
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue0.37
Enterprise Value/Gross Profit2.68
Enterprise Value/Ebitda1.79
Forecast
1Y Price Target
$11.25Price Target Upside134.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Sensus Healthcare Business Overview & Revenue Model
Company DescriptionSensus Healthcare, Inc. (SRTS) is a medical device company that specializes in providing non-invasive and cost-effective treatments for non-melanoma skin cancers and keloids using superficial radiation therapy (SRT). The company's flagship product, the SRT-100, is designed to provide patients with an alternative to surgical procedures for treating skin conditions. Sensus Healthcare operates within the healthcare sector, focusing on dermatology and oncology markets.
How the Company Makes MoneySensus Healthcare generates revenue primarily through the sale and leasing of its SRT devices, including the SRT-100, to dermatologists, oncologists, and hospitals. The company also earns revenue from service agreements, providing maintenance and support for its installed devices. Additionally, Sensus may benefit from partnerships with healthcare providers and institutions that expand the reach and adoption of its technology. These arrangements can include collaborative research, marketing initiatives, and training programs to enhance the utilization of SRT treatments.
Sensus Healthcare Financial Statement Overview
Summary
Sensus Healthcare shows strong revenue and profit growth, with a robust balance sheet characterized by low leverage and high equity. However, cash flow remains a challenge due to negative free cash flow, indicating a need for improved cash management strategies.Income Statement
Sensus Healthcare showed remarkable revenue growth of 71.3% from the previous year. The gross profit margin improved significantly to 58.4%, reflecting increased operational efficiency. Net profit margin also improved substantially to 15.9%, indicating enhanced profitability. However, the EBIT margin of 19.3% and EBITDA margin of 19.3% suggest room for improvement in controlling operating expenses.78
Positive
Balance Sheet
The company maintains a strong equity position with an equity ratio of 89.8%, demonstrating financial stability. The debt-to-equity ratio is low at 0.01, indicating minimal leverage and reduced financial risk. Return on equity improved significantly to 11.9%, showcasing effective utilization of shareholder funds. Overall, the balance sheet reflects solid financial health.85
Very Positive
Cash Flow
Sensus Healthcare's free cash flow improved but remains negative, indicating potential challenges in cash management. The operating cash flow to net income ratio is negative, suggesting a need to enhance cash generation from operations. Despite these challenges, the free cash flow deficit has narrowed, showing some progress towards achieving positive cash flows.60
Neutral
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 39.49M | 41.81M | 24.41M | 44.53M | 27.04M | 9.58M | Gross Profit |
| 22.12M | 24.43M | 14.06M | 29.63M | 16.99M | 5.25M | EBIT |
| 2.56M | 8.09M | -382.00K | 14.83M | 4.12M | -8.23M | EBITDA |
| 2.79M | 8.52M | 79.00K | 14.83M | 4.73M | -6.10M | Net Income Common Stockholders |
| 1.80M | 6.65M | 485.00K | 24.24M | 4.12M | -4.72M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 19.07M | 22.06M | 23.15M | 25.52M | 14.52M | 14.91M | Total Assets |
| 60.21M | 62.16M | 53.71M | 56.73M | 32.24M | 28.01M | Total Debt |
| 654.00K | 602.00K | 783.00K | 1.02M | 225.00K | 1.38M | Net Debt |
| -18.42M | -21.45M | -22.36M | -24.50M | -14.29M | -13.52M | Total Liabilities |
| 7.18M | 6.34M | 4.87M | 8.67M | 6.22M | 6.51M | Stockholders Equity |
| 53.03M | 55.83M | 48.84M | 48.07M | 26.02M | 21.50M |
| Cash Flow | Free Cash Flow | ||||
| 4.64M | -1.11M | -2.37M | -1.57M | -414.00K | -792.73K | Operating Cash Flow |
| 4.68M | -831.00K | -2.15M | -1.41M | -286.00K | -434.18K | Investing Cash Flow |
| -50.00K | -276.00K | -187.00K | 14.84M | 129.00K | 7.03M | Financing Cash Flow |
| -285.00K | 15.00K | -40.00K | -2.43M | -231.00K | 210.01K |
Sensus Healthcare Technical Analysis
Positive
4.80
Price Trends
4.61
Positive
5.45
Negative
6.16
Negative
Market Momentum
<0.01
Negative
56.18
Neutral
66.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Positive. The current price of 4.8 is above the 20-day moving average (MA) of 4.52, above the 50-day MA of 4.61, and below the 200-day MA of 6.16, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.18 is Neutral, neither overbought nor oversold. The STOCH value of 66.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRTS.
Sensus Healthcare Risk Analysis
Sensus Healthcare disclosed 25 risk factors in its most recent earnings report. Sensus Healthcare reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sensus Healthcare Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $77.79M | 43.68 | 3.46% | ― | 24.75% | -61.29% | |
52 Neutral | $5.19B | 3.04 | -44.20% | 2.82% | 16.59% | -0.39% | |
45 Neutral | $69.55M | ― | -51.63% | ― | 11.26% | -14.21% | |
43 Neutral | $69.04M | ― | 91.63% | ― | -55.47% | 24.92% | |
36 Underperform | $83.38M | ― | -55.14% | ― | -99.43% | -69.40% | |
33 Underperform | $21.93M | ― | -125.43% | ― | ― | 2.98% |
* Healthcare Sector Average
Performance Comparison
SRTS
Sensus Healthcare
4.80
-1.03
-17.67%
EDAP
EDAP TMS
1.90
-4.12
-68.44%
CLSD
Clearside Biomedical
0.88
-0.47
-34.81%
VOR
Vor Biopharma
0.18
-1.54
-89.53%
ADAG
Adagene
1.56
-1.05
-40.23%
Sensus Healthcare Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q1-2025)
| % Change Since: 3.00%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook for Sensus Healthcare. While there were significant highlights such as the expansion of the FDA program and increased brand visibility, the company faced challenges with a revenue decline and increased operating expenses leading to a net loss for the quarter. However, there is optimism for the remainder of 2025 with expected revenue growth from the FDA program and international expansion.Q1-2025 Updates
Positive Updates
Expansion of Fair Deal Agreement Program
The Fair Deal Agreement (FDA) program showed a 65% increase in patient treatments from Q4 2024 to Q1 2025. This program is expected to significantly contribute to revenue in the second half of 2025, with plans to sign 3-5 additional multi-site FDA customers in 2025.
Strong Marketing and Brand Visibility
Sensus Healthcare expanded its brand visibility through participation in major industry events and targeted marketing activities, leading to a strong pipeline of new FDA opportunities.
International Expansion and Product Innovation
The company is progressing in its international strategy, attending major conferences such as ESTRO in Vienna and is set to exhibit at the Australian Academy of Dermatology Annual Meeting. Additionally, enhancements to the transdermal infusion system (TDI) are underway, with an expected FDA determination by year-end.
Negative Updates
Revenue Decline
Revenue for Q1 2025 was $8.3 million, down from $10.7 million in Q1 2024, primarily due to lower unit sales to the largest customer.
Increased Operating Expenses
Operating expenses were significantly higher compared to the previous year, with G&A expenses rising to $2.2 million from $1.6 million, and selling and marketing expenses increasing to $2.2 million from $1.3 million.
Net Loss in Q1 2025
Sensus reported a net loss of $2.6 million or $0.16 per share in Q1 2025, compared to a net income of $2.3 million or $0.14 per diluted share in Q1 2024.
Company Guidance
During the Sensus Healthcare Q1 2025 earnings call, the company reported first-quarter revenues of $8.3 million, a decrease from $10.7 million in Q1 2024, primarily due to reduced unit sales to a major customer. Despite a net loss of $2.6 million or $0.16 per share, the company outlined significant investments in sales, marketing, and R&D, with operating expenses rising to $2.2 million in G&A and $2.6 million in R&D. Sensus shipped 21 SRT systems during the quarter, increasing its installed base to over 880 units, with expectations to surpass 900 by Q2 and reach 1,000 within a year. The company highlighted a 65% increase in patient treatments from its fair deal agreements, underscoring anticipated contributions to revenue in the second half of 2025. Adjusted EBITDA was negative $2.5 million, with the company maintaining a strong cash position of $19.1 million and no debt. Sensus is optimistic about returning to profitability in the upcoming quarters as its fair deal agreements mature and contribute more significantly to revenue.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.